NEWSROOM

Stay current with MiRXES

Media Releases

Keep up to date with our latest news and activities as we continue to innovate and develop our science and technology, bringing novel products to market – from Singapore to the World.

Unveiling ceremony - Mirxes receives FDA's Breakthrough Device Designation for GASTROClear

18 June 2024

Mirxes Japan Scores Grant to Develop Novel Cancer Screening Test in Japan

Singapore – 11 June 2024 – Mirxes is pleased to announce that our fully-owned subsidiary, Mirxes Japan, has secured a grant of up to 20 million yen (S$172,000) from the Japan External Trade Organization (JETRO). This grant is a testament of Mirxes Japan’s effort and growth in Japan, and will support the development and validation of a new non-invasive cancer biomarker screening test service specifically for the Japanese market.

Mirxes-and-PULSE-TCM-launches-holistic-East-Meets-West-community-health-screening-pilot

24 May 2024

Mirxes and PULSE TCM launches holistic “East Meets West” community health screening pilot

Singapore, 25 May 2024 – In a First-In-Singapore collaboration, leading RNA
technology company Mirxes and PULSE TCM, a renowned provider of traditional
Chinese Medicine (TCM) services, today launched the holistic “East Meets West”
Community Health Screening Pilot at Bukit Gombak. Witnessed by Ms Low Yen Ling,
Senior Minister of State, Ministry of Culture, Community and Youth, Ministry of Trade
and Industry, Mayor of South West District and Grassroots Adviser to Bukit Gombak
Grassroots Organisations, this pilot represents a novel approach towards integrating contemporary Western precision diagnostic technology with Eastern TCM wisdom, aimed at creating an integrated approach to preventive and personalised healthcare
for a Healthier Singapore.

Official-opening-of-Singapore’s-pioneering-public-private-partnership-centre-for-specialty-molecular-testing

13 May 2024

Official opening of Singapore’s pioneering public-private partnership centre for specialty molecular testing

Singapore, 13 May 2024 – The National University Hospital (NUH) and Mirxes are proud to announce the official opening of the NUH DMOC@Biopolis, one of Singapore’s first publicprivate partnership centres for specialty molecular testing. The NUH DMOC@Biopolis is an extension of NUH’s Diagnostic Molecular Oncology Centre (DMOC) that co-locates and integrates with Mirxes’ clinical laboratory, M Diagnostics at Biopolis. The Centre was inaugurated today by Deputy Prime Minister, Coordinating Minister for Economic Policies, and Chairman of the National Research Foundation (NRF), Mr Heng Swee Keat.

Unveiling ceremony - Mirxes receives FDA's Breakthrough Device Designation for GASTROClear

10 August 2023

Mirxes receives FDA’s Breakthrough Device Designation for GASTROClear to advance blood-based cancer early detection

Mirxes announced today that its flagship product GASTROClearTM, a PCR-based in vitro diagnostic test for early detection of gastric (stomach) cancer, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). Globally, this marks the first time that 1) a blood miRNA test, 2) an in vitro diagnostic (IVD) test for early detection of gastric cancer, and 3) a molecular in vitro diagnostic test developed in Southeast Asia, has received a Breakthrough Device Designation from the U.S. FDA.

2023-01-10 - Big3 MIRXES Shoot0302

25 July 2023

Mirxes secures US$50 Million in Series D funding and files listing application with The Stock Exchange of Hong Kong Limited

Mirxes announced today the successful completion of its Series D funding round, securing a total of US$50 million. In addition to securing the Series D funding, Mirxes is pleased to announce that it has filed the listing application with The Stock Exchange of Hong Kong Limited (HKEX) under Chapter 18A of the Rules Governing the Listing of Securities on HKEX. 

MOU Signing at G20 Summit

29 November 2022

MiRXES and PT ELION inked landmark MOU to develop blood-based multi-cancer early detection solutions optimized for the Indonesian population

MiRXES signed a Memorandum of Understanding with PT ELION MEDIKA INDONESIA (PT ELION) to validate and commercialize MiRXES’s microRNA cancer blood tests for stomach and lung cancers in Indonesia, and establish CADENCE-ID, a joint project for the optimization and validation of a novel multi-cancer blood test, based on blood-borne circulating miRNA and DNA methylation biomarkers in the Indonesian population, for up to nine high incidence and high mortality cancers.

Dr Wang Jian (left) and Dr Zhou Lihan (right) unveiling the T10 Sequencer 2

22 November 2022

MiRXES Unveiled APAC’s First T10 Ultra-high Throughput Sequencing Platform

MiRXES together with Guest of Honor Dr. Wang Jian, Co-founder and Chairman of BGI Group, unveiled today the cutting-edge DNBSEQ-T10×4RS Genetic Sequencing System (T10), the world’s largest and highest throughput next generation sequencer. The T10 sequencing platform will provide a significant boost to Singapore’s sequencing power and build a high-resolution spatial transcriptomics pipeline in Singapore.
mirxes multi-cancer screening test lab

28 September 2022

MiRXES collaborates with NUHCS and NHCS to launch Southeast Asia’s first Asian-focused multi-center study to advance pulmonary hypertension early detection

Singapore-headquartered biotech MiRXES, National University Heart Centre, Singapore (NUHCS) and National Heart Centre Singapore (NHCS) launch SPHERE (Singapore Pulmonary Hypertension Early detection with miRNA biomarkErs) study to identify biomarkers that are relevant to early detection of pulmonary hypertension with the aim to improve Asian patient outcomes and save lives.

NCIS-LRS Website1

18 September 2022

MiRXES Donates SG$88,902 to NCIS Cancer Fund through Let’s Ride! Singapore Closing Ride

MiRXES announced today the donation of SG$88,902 to the National University Cancer Institute, Singapore (NCIS) Cancer Fund, a sub-fund of NUHS Fund, at the closing ceremony of Let’s Ride! Singapore today, to assist less fortunate cancer patients with critical cancer treatments. This event was graced by Guest-of-Honor, Ms. Low Yen Ling, Minister of State, Ministry of Trade and Industry & Ministry of Culture, Community and Youth, and Mayor of South West District, who witnessed the cheque presentation ceremony.

Lab Opening 1

7 July 2022

MiRXES strengthens global fight against cancer with launch of world’s first research project for a multi-cancer screening test using microRNA and multi-omics technology

MiRXES announced announced today the signing of a Memorandum of Understanding (MOU) that launched Project CADENCE (CAncer Detected Early caN be CurEd) and also officially opened its R&D and clinical diagnostic labs in Biopolis, Singapore.
MOU2

7 June 2022

MiRXES – BGI Research – MGI Strategic Partnership to Scale Cutting-Edge Spatial Multi-Omics Research Capabilities in Asia-Pacific Region

MiRXES has formed a strategic partnership with BGI-Research, an internationally renowned genomics research institution, and MGI, a leading developer and provider of high-throughput sequencing platforms, to accelerate spatio-temporal transcriptomics and multi-omics research in human development and diseases.
i4.0_News

27 May 2022

MiRXES Opens Southeast Asia’s First Industry 4.0 In Vitro Diagnostic Manufacturing Facility

MiRXES announced today the opening of the first industry 4.0 (i4.0) in vitro diagnostic (IVD) manufacturing facility in Southeast Asia. This S$8 million facility at JTC MedTech Hub is the largest i4.0 IVD manufacturing site at in Southeast Asia at 15,000 square feet. Guest-of-Honour, Mr Gan Kim Yong, Minister for Trade and Industry, graced the opening ceremony.
Prof_Tony_news.jpg

12 April 2022

MiRXES Welcomes Professor Tony Mok to Scientific Advisory Board

MiRXES announced today the appointment of Professor Tony Mok, a world-renowned medical oncologist, to its Scientific Advisory Board (SAB). Professor Mok co-founded the Lung Cancer Research Group, Chinese Thoracic Oncology Research Group and Asia Thoracic Oncology Research Group and has led multiple multi-national studies that help establish the global standard on personalized medicine for lung cancer.

2021 Releases

Dr-Zhou-Lihan-from-MiRXES.jpg

22 November 2021

MiRXES’s Founders Named EY Entrepreneur Of The Year 2021 Singapore

MiRXES announced today that Dr. Lihan ZHOU, Co-founder and Chief Executive Officer at MiRXES, Dr. Ruiyang ZOU, Co-founder and Chief Technology Officer at MiRXES and Mr. Isaac HO, Chief Investment Officer at MiRXES, have been named EY Entrepreneur Of The Year (EOY) 2021 Singapore by professional services organization, EY.
mendaki.png

23 October 2021

Yayasan MENDAKI and MiRXES announce SG$140,000 MENDAKI - MiRXES scholarship scheme

Yayasan MENDAKI and MiRXES, are pleased to announce today the setting up of the “MENDAKI – MIRXES Scholarship” for Malay/Muslim students who are pursuing undergraduate and post-graduate studies in Life and Biomedical Sciences. In addition to the scholarships, the students will also receive internship opportunities and securing employment opportunities with MiRXES upon their graduation.
daliu-1.jpg

21 September 2021

MiRXES Board of Directors welcomes strategic investor Da Liu from CR-CP Life Science Fund to fast-track groundbreaking early cancer diagnostics

MiRXES announced today the appointment of Mr. Da LIU to its Board of Directors. Currently the Managing Director of CR-CP Life Science Fund, Mr. Liu leads investments in life sciences companies globally, especially those in emerging sectors such as RNA therapeutics and cancer screening.

28 July 2021

MiRXES Welcomes Genomics Expert to Scientific Advisory Board

Dr. Holger Heyn, an expert in single-cell genomics and spatial transcriptomics, has joined the Scientific Advisory Board of MiRXES to help advance its development of RNA-powered multi-omics solutions for research and diagnostics.

8 July 2021

MiRXES Secures US$77 Million Series C Funding to Accelerate Multi-Cancer Early Detection Pipeline

This new capital will support MiRXES’s growth as a global leader in cancer early detection tests and preventive healthcare.

24 February 2021

Study Validates Performance of MiRXES qPCR Platform

This study shows MiRXES qPCR profiling platform to be superior in reproducibility and detection rate compared to other commercial microRNA profiling platforms when used for validation of blood-based microRNA biomarkers.

Media and Investor Contact

For media enquiries, please email: communications@mirxes.com

ABOUT

SOLUTIONS

TECHNOLOGY

PIPELINE

NEWSROOM

Copyright © 2024 MiRXES Pte Ltd. All rights reserved. | Privacy Policy
Scroll to Top